Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "David Finegold" Clear advanced filters

  • A survey of the ethical practices of bioscience companies suggests that although most firms feature ethics in their mission statement or code of conduct, fewer than half of the companies surveyed have made any formal efforts to assess how well these approaches are working.

    • David Finegold
    • Allison Moser
    Special Features
    Nature Biotechnology
    Volume: 24, P: 285-290

  • Competitive intelligence (CI) gathering is essential to developing a biotech firm's business strategy, but few startups have sufficient support systems in place to do CI effectively. This article, the first of two on the topic, addresses why it is important and how to do it.

    • Salvador Carlucci
    • Anthony Page
    • David Finegold
    Comments & Opinion
    Bioentrepreneur
    P: 1-3

  • Turning competitive intelligence into knowledge is a multi-layered process. In this second of two articles on competitive intelligence, we outline the steps involved and point out some of the potential pitfalls.

    • David Finegold
    • Salvador Carlucci
    • Anthony Page
    Comments & Opinion
    Bioentrepreneur
    P: 1-3

  • Working with patient advocacy groups poses many challenges to entrepreneurs, but the benefits can be substantial. Here, we examine the relationship between biotech PTC Therapeutics and Parent Project Muscular Dystrophy to highlight some key factors for success in such partnerships.

    • Anne-Laure Winkler
    • David Finegold
    Comments & Opinion
    Bioentrepreneur
    P: 1-4